Safety and Immunogenicity of Recombinant DNA and Adenovirus Expressing L523S Protein in Early Stage Non-Small Cell Lung Cancer

INCLUSION CRITERIA: * Histologically and surgical confirmed diagnosis and stage of IB, IIA, or IIB non-small cell lung cancer (NSCLC) according to the Revised International System for Staging Lung Cancer * Primary surgical resection of lung cancer greater than or equal to 4 weeks and less than or equal to 3 years prior to the Day 0 visit * No evidence of disease by standard diagnostic tests * Chest X-ray and physical examination showing no active disease * Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1 * WBC count greater than or equal to 3,000 cells/mm3 and ANC greater than or equal to 1,500 cells/mm3 * Hemoglobin value greater than or equal to 10.0 g/dL and a platelet count greater than or equal to 125,000 cells/mm3 * Adequate renal function (defined as serum creatinine \<1.5 times the upper limit of normal for females and males) * Normal hepatic function (defined as serum bilirubin \<1.5 times the upper limit of normal, AST \<2.5 times the upper limit of normal and alkaline phosphatase \<1.5 times the upper limit of normal) * Ability to understand and willingness to sign an IRB-approved written consent prior to study enrollment * Female patients must be greater than or equal to 60 years of age, or greater than or equal to 5 years amenorrhea or surgically sterile * Male patients who are capable of fathering a child and whose partners are capable of having a child must agree to use adequate contraception for 6 months after enrollment (for men or women-surgical sterilization; for women-hormonal contraceptives, vaginal ring or IUD) * Absolute CD4+ cell count of \>200 cells/mm3 EXCLUSION CRITERIA: * Received pre- or post-operative radiotherapy * Received prior biologic, immunologic, or gene therapy for cancer * Received an investigational drug (new chemical entity) within three months of study entry * Received antibiotics within 2 weeks of Day 0 visit * Received systemic or inhaled corticosteroids or immunosuppressive therapy within 4 weeks of Day 0 visit (Use of topical corticosteroids and/or eye drops containing glucocorticosteroids is acceptable) * History of active autoimmune diseases such as, but not limited to, systemic lupus erythematosis, sarcoidosis, rheumatoid arthritis, glomerulonephritis, vasculitis, or inflammatory bowel disease * History of bleeding in stools and/or diarrhea within 4 weeks of Day 0 visit * History of anaphylaxis or severe allergic reaction to vaccines or unknown allergens * Received any commercial vaccine within 2 weeks of Day 0 visit * Received a major organ allograft * Current or previous diagnosis of paraneoplastic syndrome * Evidence of a clinically significant active pulmonary infection, emphysema, FeV1 less than or equal to 50% predicted, DLCO less than or equal to 50% predicted, pulse oximetry less than or equal to 92% at the time of study entry * Known to be HIV positive * Results of virology screening indicate positive serology for HCV (hepatitis C virus) and/or HBsAG (hepatitis B surface antigen). Positive serology for HBV antibodies is allowed. * History of other malignancies at other sites, except effectively treated non-melanoma skin cancers, superficial bladder cancer or carcinoma in situ of the cervix or an effectively treated malignancy that has been in remission for greater than 5 years and is highly likely to have been cured * Uncontrolled medical problems (neurological, cardiovascular, gastrointestinal, genitourinary or other illness) considered as unwarranted high risk for investigational new drug treatment * Patient is lactating * Staging classification of TX or NX or MX * Prior adjuvant chemotherapy within 8 weeks prior to the Day 0 visit